How to Cite
Abstract
The article analyzes the literature aiming the evolution of problems and prospects in the use of different types of vaccines for the HIV-infection prevention. The questions of the study and the development of immunogens capable to induce different links of immune response and to generate protective immunity are elucidated. The results of the research aimed at studying the spatial structure of the HIV envelope protein epitopes and design of vaccines that would present effectively these epitopes to the immune system are considered. The data of vector and genetic engineering vaccines tests and their mechanism of action due to the induction of broadly neutralizing antibodies have been analyzed.References
Информационный бюллетень ВОЗ. – Июль 2015 г. – № 360. Режим доступу: http://www.who.int/mediacentre/factsheets/fs360/ru/
Global AIDS response progress reporting 2015. Режим доступу: http://www.unaids.org/sites/default/files/media_asset/JC2702_GARPR2015guidelines_en.pdf
Diversity considerations in HIV-1 vaccine selection / B. Gaschen, J. Taylor, K. Yusim et al. // Science. – 2002. – Vol. 296. – P. 2354–2360.
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques / A.J. Hessell, P. Poignard, M. Hunter et al. // Nat. Med. – 2009 Aug. – Vol. 15. – P. 951–954.
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers / A.J. Hessell, E.G. Rakasz, P. Poignard et al. // PLoS pathogens. – 2009 May. – Vol. 5, № 5. – e1000433.
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L / A.J. Hessell, E.G. Rakasz, D.M. Tehrani et al. // J. Virology. – 2010 Feb. – Vol. 84, № 3. – P. 1302–1313.
Johnston M.I. HIV vaccine development – improving on natural immunity / M.I. Johnston, A.S. Fauci // N. Engl. J. Med. – 2011. – Vol. 365, № 10. – P. 873–875.
Клинические испытания первой отечественной анти-ВИЧ/СПИД-вакцины / Р.М. Хаитов, А.В. Решетников, И.Г. Сидорович и др. – Москва, 2009. – 656.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand / S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al. // N. Engl. J. Med. – 2009. – Vol. 3, № 361. – P. 2209–2220.
O'Connell R.J. HIV vaccine efficacy and immune correlates of risk / R.J. O'Connell, J.L. Excler // Curr. HIV Res. – 2013. – Vol. 11, № 6. – P. 450–463.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial / B.F. Haynes, P.B. Gilbert, M.J. McElrath et al. // N. Engl. J. Med. – 2012. – Vol. 366, № 14. – P. 1275–1286.
Kwong P.D. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies / P.D. Kwong, J.R. Mascola // Immunity. – 2012. – Vol. 21, № 37. – P. 412–420.
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family / M. Bonsignori, J. Pollara, M.A. Moody et al. // J. Virology. – 2012. – Vol. 86, № 21. – P. 11521–11532.
Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5–7 November 2012 / M.P. Girard, V. Picot, C. Longuet et al. // Vaccine. – 2013. – Vol. 31, № 29. – P. 2979–2983.
Characteristics of the earliest cross-neutralizing antibody response to HIV-1 / I. Mikell, D.N. Sather, Kalams et al. // PLoS Pathogens. – 2011. – Vol. 7, № 1. – P. e1001251.
Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1 / D.N. Sather, S. Carbonetti, D.C. Malherbe [et al.] // J. Virol. – 2014. – Vol. 88, № 22. – P. 12968-12981.
HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T-cell decline and high viral load during acute infection / E.S. Gray, M.C. Madiga, T. Hermanus et al. // J. Virology. – 2011. – Vol. 85, № 10. – P. 4828–4840.
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection / D.N. Sather, J. Armann, L.K. Ching et al. // J. Virology. – 2009. – Vol. 83, № 2. – P. 757–769.
Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG / J.W. Eichberg, K.K. Murthy, R.H. Ward, A.M.Prince // AIDS research and human retroviruses. – 1992. – Vol. 8, № 8. – P. 1515.
Antibody neutralization and escape by HIV-1 / X. Wei, J.M. Decker, S.Wang et al. // Nature. – 2003. – Vol. 422, № 6929. – P. 307–312.
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus / H.X. Liao, Rebecca Lynch, Tongqing Zhou et al. // Nature. – 2013. – Vol. 496. – P. 469–476.
Exceler J.L. Novel direction in HIV-1 vaccines revealed from clinical trials / J.L. Exceler, G.D. Tomaras, N.D. Russell // Curr. Opin. HIV AIDS. – 2013. – Vol. 8, № 5. – P. 421–431.
Immune clearance of highly pathogenic SIV infection / S.G. Hansen, M. Piatak Jr, A.B. Ventura, C.M. Hughes. // Nature. – 2013. – Vol. 502. – P. 100–104.
Winders J. HIV vaccine produces no adverse effects in trials / J. Winders // Western news. – 03.09.2013. Режим доступу: http://news.westernu.ca/2013/09/hiv-vaccine-produces-no-adverse-effects-in-trials/
30 лет спустя: в России тестируют вакцину против ВИЧ. Режим доступа: http://medportal.ru/mednovosti/news/2014/10/15/436hiv/
Mascola J.R. HIV-1 neutralizing antibodies: understanding nature's pathways / J.R. Mascola, B.F. Haynes // Immunol. Rev. – 2013. – Vol. 254, № 1. – P. 225–244.
van Gils M.J. Broadly neutralizing antibodies against HIV-1: templates for a vaccine / M.J. van Gils, R.W. Sanders // Virology. – 2013. – Vol. 435, № 1. – P. 46–56.
Hoxie J.A. Toward an antibody-based HIV-1 vaccine / J.A. Hoxie // Annu. Rev. Med. – 2010. – Vol. 61. – P. 135–152.
Sadanand S. Broadly neutralizing antibodies against HIV: New insights to inform vaccine design / S. Sadanand, T.J. Suscovich, G. Alter // Annu. Rev. Med. – 2015 Nov 9. [Epub ahead of print]. Режим доступу: http://www.ncbi.nlm.nih.gov/pubmed/26565674
Comparable Antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research / L. Wieczorek, S.J. Krebs, V. Kalyanaraman et al. // J. Virol. – 2015. – Vol. 89, № 15. – P. 7478–7493.
Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice / R. Chapman, H. Stutz, W.Jr. Jacobs et al. // PLoS. One. – 2013. – Vol. 8, № 8. – e71601. doi: 10.1371/journal.pone.0071601. eCollection 2013h
The use of directed evolution to create a stable and Immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen / R. Chapman, W.R. Bourn, E. Shephard [et al.] // PLoS. One. – 2014. – Vol. 9, № 7. – e103314. doi: 10.1371/journal.pone.0103314. eCollection 2014